Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05974293
Other study ID # 2023P002959
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date April 2024
Est. completion date September 2026

Study information

Verified date November 2023
Source Massachusetts General Hospital
Contact Anastasia Vishnevetsky, MD
Phone 2034309425
Email avishnevetsky@partners.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the safety and efficacy of nabiximols, a cannabinoid spray, for the treatment of moderate to severe spasticity in adult patients with AQP4-IgG positive and antibody-negative NMOSD. The main question it aims to answer is whether treatment with nabiximols improves patient-reported spasticity ratings compared to treatment with a placebo. This trial will also answer whether nabiximols impact pain, spasm frequency, mood, walking ability, and sleep. Participants will be mailed the treatments and placebo treatments, and will be asked to complete study visits and questionnaires remotely. There is also an optional sub-study that involves in-person visits with ultrasound imaging and in-person neurologic exams.


Description:

Patients with NMOSD often have medication-resistant and severe spasticity due to longitudinally extensive spinal cord lesions. Existing treatments are limited by their efficacy and tolerability. Cannabinoids have been shown to quantitatively improve spasticity in mouse models of neuroinflammation, and nabiximols, a cannabinoid-based oromucosal spray, have demonstrated efficacy for medication-resistant spasticity in multiple sclerosis. However, no studies have as yet explored the use of nabiximols specifically in NMOSD, and there is a significant unmet need for new symptomatic treatments in this patient population. The goal of this study is to evaluate the safety and efficacy of nabiximols spray, for the treatment of moderate to severe spasticity in adult patients with AQP4-IgG positive and seronegative NMOSD. This study is designed as a phase IIb, single-site, double-blind, randomized, placebo-controlled 2x2 crossover clinical trial, with a 2-week washout period between treatment periods. After randomization, each participant enters into Period 1, which begins with a 2-week dose escalation period with a pre-defined dose escalation scheme, followed by a 4-week stable treatment period. After completion of Period 1, all participants have a 2-week washout period and then enter Period 2, where they again complete a 2-week dose escalation period and 4-week constant treatment period. The patient-reported 0-10 numeric rating scale for spasticity (NRS-S) is the primary outcome measure. All key study procedures are performed virtually, including a weekly electronic study diary, additional weekly surveys, and 8 virtual video-based study visits including a screening visit and safety follow up visit. Additional optional in-person assessments of spasticity (neurologic exam, modified Ashworth Scale and muscle ultrasound elastography) will be performed for a selection of local participants. In total, the study has a 20-week duration per participant, from the screening visit to the final study completion for safety follow-up visit, including 12 weeks of on-treatment time.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 44
Est. completion date September 2026
Est. primary completion date April 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Confirmed diagnosis of NMOSD, meeting the International Panel for NMO Diagnosis (IPND) NMOSD criteria (Appendix 1), including NMOSD with AQP4-IgG, and NMOSD without AQP4-IgG - Aged between 18 years or older, at the time of signing the informed consent - Willing and able to give informed consent and to participate in all study procedures - Moderate to severe spasticity, as defined by a score of > 3 on the 0-10 numerical rating scale for spasticity (NRS-S) at the time of screening - Reports NMOSD-related spasticity symptoms ongoing for at least 6 months - Spasticity is determined to be causally related to an NMOSD attack in the opinion of the investigator - No relapses, and otherwise stable disease (i.e. no significant recovery from relapse or other change in disability) for at least 6 months, in the opinion of the investigator - Anti-spasticity regimen, if on medications, maintained at a stable dose for the 30 days prior to enrollment without adequate relief of spasticity symptoms. - Willing to maintain a stable dose of non-study-related anti-spasticity medication for the duration of the study, barring significant changes to their medical condition. - Willing to allow his or her primary care doctor and primary neurologist, if appropriate, to be notified of participation in the study. - Documentation of negative MOG-IgG, if diagnosis is NMOSD without AQP4-IgG positive status. Participant with presumptive diagnosis of NMOSD without AQP4-IgG and no prior MOG IgG testing can have MOG testing sent, and be eligible for participation if this is negative. - For women of childbearing potential: participants who are not lactating, not pregnant, and not planning to become pregnant in the next 8 months and who agree to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for at least 3 months after the final dose of nabiximols. - For males with partners who are females of childbearing potential: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use adequate contraception during the treatment period and for at least 3 months after the final dose of nabiximols. - Able to use the necessary electronic applications (either via smartphone, tablet, or desktop) and has an email address. Exclusion Criteria: - Consumption of cannabis herb or other cannabinoid-based drugs within 30 days prior to study entry. - Unwillingness to abstain from consumption of cannabis herb or other cannabinoid-based drugs for the duration of the study. - Known or suspected hypersensitivity or adverse reaction (including psychiatric adverse reactions) to cannabinoids or cannabinoid products, ethanol, peppermint oil or propylene glycol. - Currently receiving a prohibited medication and unwilling or unable to stop for the duration of the study. Prohibited medications include: CYP3A4 inhibitors: clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, etc.; CYP3A4 inducers: rifampicin, phenobarbital, phenytoin, St. John's Wort. Of note, the CYP3A4 inducer carbamazepine is permitted, but a stable dosage must be maintained throughout the study (no as needed dosing permitted). Other prohibited medications: regular levodopa (Sinemet, Sinemet Plus, Levodopa, L-dopa, Madopar, Benserazide), sildenafil (Viagra), fentanyl, or antiarrhythmic medications. - Receipt of an investigational medicinal product or participation in a therapeutic clinical trial within 30 days prior to the initial visit - Received a Botulinum Toxin injection within four months prior to the screening visit or unwillingness to stop receiving Botulinum Toxin injections for the relief of spasticity for the duration of the study. - Personal medical history of schizophrenia, severe personality disorders, other major psychotic disorders, or other major psychiatric disorders other than depression and anxiety. - Family history in 1st degree relatives of schizophrenia or other psychotic disorders. - Hospitalization for depression or anxiety within the 2 years prior to the screening visit. - A documented history of attempted suicide or suicidal ideation of category 4 or 5 according to the Columbia Suicide Severity Rating Scale (C-SSRS) screening, OR if in the Investigator's judgment, the participant is at risk for a suicide attempt. - Known or suspected history of a substance use disorder or heavy alcohol consumption excluding tobacco use disorder or cannabis use not meeting criteria for cannabis use disorder. - History of myocardial infarction or clinically significant ischemic heart disease, arrhythmias (other than well controlled atrial fibrillation), poorly controlled hypertension or severe heart failure. . - Significant renal or hepatic impairment, either in the opinion of the investigator, or by the following laboratory screening values: AST or ALT > 2 × upper limit of normal (ULN); Total bilirubin > 2 × ULN (unless due to Gilbert's syndrome); BUN > 2 × upper limit of normal (ULN) - History of epilepsy or recurrent seizures. - Concomitant disease or disorder that has symptoms of spasticity, and that in the opinion of the Investigator may influence the study outcome and endpoint assessment. - Any other significant medical or psychiatric condition which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study or the participant's ability to participate in the study. - Scheduled elective surgery or other procedures which require general anesthesia during the study period. - Intention to donate blood during the study. - Intention to travel internationally during the study.

Study Design


Intervention

Drug:
Nabiximols
Nabiximols is is a yellow-brown oromucosal spray solution containing 27 mg/mL of THC and 25 mg/mL of CBD.
Placebo
The placebo is a matching oromucosal spray that is identical to the investigational study product in terms of packaging, labelling, schedule of administration, dosing instructions, and appearance.

Locations

Country Name City State
United States Massachusetts General Hospital Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Michael, Levy M.D.,Ph.D. Jazz Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in mean Patient Health Questionnaire-8 (PHQ-8) scores from pre-treatment to post-treatment The Patient Health Questionnaire-8 is an 8-item self-administered depression scale Screening; Up to week 20
Other Change in mean PROMIS SF v1.0 - Anxiety 4a scores from pre-treatment to post-treatment The PROMIS SF v1.0 - Anxiety 4a scale is a 4-item self-administered anxiety questionnaire Screening; Up to week 20
Other Change in mean Floodlight-Pinching Test (PT) scores from pre-treatment to post-treatment The Floodlight-Pinching Test (PT) is a smartphone application-based test assessing hand and arm function Screening; Up to week 18
Other Change in mean Floodlight-Draw a Shape Test (DaS) scores from pre-treatment to post-treatment The Floodlight-Draw a Shape Test (DaS) is a smartphone application-based test assessing hand and arm function Screening; Up to week 18
Other Change in mean Floodlight-e-Symbol Digit Modalities Test (eSDMT) scores from pre-treatment to post-treatment The Floodlight-Draw a Shape Test (DaS) is a smartphone application-based test assessing cognition Screening; Up to week 18
Other Change in Lower Limb Muscle Tone-6 (LLMT-6) scores as measured by the modified Ashworth Scale scores from pre-treatment to post-treatment LLMT-6 is defined as the average of the 6 individual Modified Ashworth Scale (MAS) transformed scores of knee flexors, knee extensors, and plantar flexors on both sides of the body Screening; Up to week 18
Other Change in muscle shear wave speed from pre-treatment to post-treatment Muscle shear wave speed is measured using shear wave elastography, an ultrasound-based technique to assess muscle stiffness Screening; Up to week 18
Primary Change in mean Numeric Rating Scale - Spasticity (NRS-S) scores from pre-treatment to post-treatment Numeric Rating Scale - Spasticity (NRS-S) score is a 0-10 point, patient-reported scale indicating spasticity severity. Baseline; Up to week 18
Secondary Proportion of participants with NRS-S response corresponding to a minimal clinically important difference (MCID) (>18% difference) from pre-treatment to post-treatment Numeric Rating Scale - Spasticity (NRS-S) score is a 0-10 point, patient-reported, single item scale indicating spasticity severity. Baseline; Up to week 18
Secondary Proportion of participants with NRS-S response corresponding to a clinically important difference (CID) (>30% difference) from pre-treatment to post-treatment Numeric Rating Scale - Spasticity (NRS-S) score is a 0-10 point, patient-reported scale indicating spasticity severity. Baseline; Up to week 18
Secondary Change in Penn Spasm Frequency Scale (PSFS) score from pre-treatment to post-treatment The Penn Spasm Frequency Scale (PSFS) is a 2-item patient-reported scale indicating spasm frequency and severity Baseline; Up to week 18
Secondary Change in mean PROMIS NRS v1.0 - Pain Intensity 3a scores from pre-treatment to post-treatment The PROMIS NRS v1.0 - Pain Intensity 3a form is a 3-item patient-reported scale indicating worst pain, average pain, and current pain in the prior week Baseline; Up to week 18
Secondary Change in mean PROMIS SF v1.1 - Pain Interference 8a scores from pre-treatment to post-treatment The PROMIS SF v1.1-Pain Interference 8a form is an 8-item scale indicating the degree to which pain interferes with functioning Baseline; Up to week 18
Secondary Change in mean Multiple Sclerosis Spasticity Scale - 88 (MSSS-88) sub-scale 2 (pain and discomfort) scores from pre-treatment to post-treatment The Multiple Sclerosis Spasticity Scale - 88 (MSSS-88) form sub-scale 2 (pain and discomfort) is a 9-item patient-reported scale indicating the impact of spasticity on pain and discomfort Baseline; Up to week 18
Secondary Change in Floodlight-5 U-Turn Test (5-UTT) from pre-treatment to post-treatment The Floodlight-5 U-Turn Test (5-UTT) is a smartphone application-based test that evaluates ambulation, and specifically turn speed in seconds Baseline; Up to week 18
Secondary Change in Floodlight-2 Minute Walk Test (2MWT) from pre-treatment to post-treatment The Floodlight-2 Minute Walk Test (2MWT) is is a smartphone application-based test that evaluates ambulation speed in seconds Baseline; Up to week 18
Secondary Change in mean Multiple Sclerosis Spasticity Scale - 88 (MSSS-88) sub-scale 5 (walking) scores from pre-treatment to post-treatment The Multiple Sclerosis Spasticity Scale - 88 (MSSS-88) form sub-scale 2 (pain and discomfort) is a 10-item patient-reported scale indicating the impact of spasticity on walking Baseline; Up to week 18
Secondary Change in PROMIS SF v1.0 - Sleep Disturbance 4A from pre-treatment to post-treatment The PROMIS SF v1.0 - Sleep Disruption 4A is a 4-item patient-reported scale indicating sleep quality Baseline; Up to week 18
Secondary Change in Numeric Rating Scale-Sleep Disruption (NRS-SD) from pre-treatment to post-treatment The Numeric Rating Scale-Sleep Disruption (NRS-SD) is a single-item 0-10 scale where participants can indicate the degree to which spasticity impacts sleep Baseline; Up to week 18
Secondary Proportion of participants reporting 'very much improved,' 'much improved,' and 'slightly improved' symptoms in the Global Impression of Change (GIC) by subject (SGIC) scores from pre-treatment to post-treatment The Global Impression of Change (GIC) by subject (SGIC) is a 7-point, single-item scale indicating the direction and degree of change that participants experience Baseline; Up to week 18
Secondary Change in Visual Analogue Scale - Quality of Life (VAS-QL) from pre-treatment to post-treatment The Visual Analogue Scale - Quality of Life (VAS-QL) is a 100mm visual analog scale ranging from 0 (very low) to 100 (very high) on which respondents record their perception of quality of life Baseline; Up to week 18
Secondary Proportion of participants who are tolerant of treatment Tolerance is defined as not discontinuing study drug and at least 50% compliance Screening; Up to week 18
Secondary Proportion of participants who are tolerant of treatment Tolerance is defined as not discontinuing study drug and at least 50% compliance Screening; Up to week 20
Secondary Number of participants with treatment-emergent adverse events while on each treatment Treatment-emergent adverse events will be tabulated for each arm during each study period and compared between treatment and placebo Screening; Up to week 20
Secondary Columbia-Suicide Severity Rating Scale (C-SSRS) Score at Screening and at each subsequent time-point with reference to the last assessment The Columbia-Suicide Severity Rating Scale is assessment tool that evaluates suicidal ideation and behavior Screening; Up to week 20
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05559255 - Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI N/A
Completed NCT03908580 - MEDITOXIN® Treatment in Subjects With Post-Stroke Upper Limb Spasticity Phase 4
Not yet recruiting NCT04550793 - Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
Recruiting NCT05432999 - Extracorporeal Shockwave Therapy for Spasticity in People With Spinal Cord Injury N/A
Completed NCT05687097 - Untreated Sleep Apnea as an Aggravating Factor for Other Secondary Medical Conditions After Spinal Cord Injury
Active, not recruiting NCT05562453 - Performance and Long-term Safety of FlowOx2.0™ in Patients With Multiple Sclerosis - Impact on Spasticity and Pain N/A
Recruiting NCT06214975 - EXOPULSE Mollii Suit, Motor Function & Stroke (EXOSTROKE 2) N/A
Recruiting NCT05464160 - Focal Muscular Vibration in Patients With Severe Acquired Brain Injury N/A
Completed NCT04130295 - Influence of Wearable Intensive Nerve Stimulation on Spasticity and Function in Persons With Spinal Cord Injury N/A
Recruiting NCT06070233 - Radiosurgery Treatment for Spasticity Associated With Stroke, SCI & Cerebral Palsy N/A
Completed NCT03747900 - Dry Needling and Botulinum Toxin in the Management of Poststroke Spasticity N/A
Completed NCT03307135 - Medical Spastic Patient Machine Interface MSPMI : Biomechanical and Electrophysiological Assessment of the Triceps Surae Spasticity N/A
Recruiting NCT05070780 - Neurophysiological Evaluation of Muscle Tone
Recruiting NCT04620707 - RGS@Home: Personalized 24/7 Home Care Post-stroke N/A
Recruiting NCT06109129 - Investıgatıon Of The Effectıveness Of The Mollıı Suıt In Chıldren Wıth Ambulatory Cerebral Palsy N/A
Enrolling by invitation NCT05598736 - Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain N/A
Completed NCT05103202 - Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
Active, not recruiting NCT05626790 - Effects of PNF and Static Stretching on Architecture and Viscoelastic Properties of Hemiplegic Elbow N/A
Recruiting NCT04904016 - Pilot Investigation to Evaluate FlowOx2.0™ for Experimental Treatment of Spasticity N/A
Withdrawn NCT05887479 - The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity Phase 4